Home » Stocks » CTMX

CytomX Therapeutics, Inc. (CTMX)

Stock Price: $7.85 USD -0.01 (-0.13%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 470.30M
Revenue (ttm) 100.36M
Net Income (ttm) -32.89M
Shares Out 46.15M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $7.85
Previous Close $7.86
Change ($) -0.01
Change (%) -0.13%
Day's Open 7.86
Day's Range 7.53 - 7.92
Day's Volume 1,413,822
52-Week Range 3.60 - 15.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

-Broad advancement of clinical pipeline-

GlobeNewsWire - 4 days ago

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class o...

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

GlobeNewsWire - 3 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transformi...

GlobeNewsWire - 3 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transformi...

GuruFocus - 4 weeks ago

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm entered an 8.9% stake in CytomX Therapeutics Inc. (NASDAQ:CTMX).

The Motley Fool - 1 month ago

All four biotechs announced the pricing of stock offerings.

Other stocks mentioned: EDIT, INO
GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transformi...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transformi...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

24/7 Wall Street - 2 months ago

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, KLDO, MGTA
GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

Seeking Alpha - 3 months ago

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 11.11% and 1.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 3 months ago

Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT Company to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT

Zacks Investment Research - 3 months ago

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

-Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT- -Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT-

GlobeNewsWire - 4 months ago

Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class ...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class...

Seeking Alpha - 6 months ago

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class ...

Zacks Investment Research - 6 months ago

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 7 months ago

NEW YORK, July 20, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. between May 17, 2018, and May 13, 2...

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - July 20, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc.

Newsfile Corp - 7 months ago

Los Angeles, California--(Newsfile Corp. - July 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Th...

24/7 Wall Street - 7 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, KLDO, MGTA
Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - July 17, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc.

Newsfile Corp - 7 months ago

Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Th...

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - July 16, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc.

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - July 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securiti...

Newsfile Corp - 7 months ago

Los Angeles, California--(Newsfile Corp. - July 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Th...

Newsfile Corp - 7 months ago

Los Angeles, California--(Newsfile Corp. - July 15, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Th...

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc. ("CytomX" or "the Company") (Nasdaq...

Newsfile Corp - 7 months ago

Los Angeles, California--(Newsfile Corp. - July 14, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Th...

Newsfile Corp - 7 months ago

Los Angeles, California--(Newsfile Corp. - July 13, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Th...

PRNewsWire - 7 months ago

NEW YORK, July 10, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018...

PRNewsWire - 7 months ago

NEW YORK, July 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018,...

Business Wire - 7 months ago

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $CTMX #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of CytomX Therapeutics, Inc. (NASDAQ: CTMX) filed ...

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - June 30, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against CytomX Therapeutics, Inc. (NYSE:...

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - June 29, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. ("CytomX" or the "Company") ...

Business Wire - 8 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May 13,...

Zacks Investment Research - 8 months ago

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Newsfile Corp - 8 months ago

New York, New York--(Newsfile Corp. - June 26, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX" or...

PRNewsWire - 8 months ago

NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CytomX Therapeutics Inc. ("CytomX" or the "Company") (NASDAQ: CTMX) and certa...

PRNewsWire - 8 months ago

NEW YORK, June 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018...

Newsfile Corp - 8 months ago

New York, New York--(Newsfile Corp. - June 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) ("CytomX" or...

GlobeNewsWire - 8 months ago

Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing Clinical Studies Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing...

About CTMX

CytomX Therapeutics operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma;... [Read more...]

Industry
Biotechnology
IPO Date
Oct 8, 2015
CEO
Sean McCarthy
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
CTMX
Full Company Profile

Financial Performance

In 2020, CTMX's revenue was $100.36 million, an increase of 74.58% compared to the previous year's $57.49 million. Losses were -$32.89 million, -67.83% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is 12.56, which is an increase of 60.00% from the latest price.

Price Target
$12.56
(60.00% upside)
Analyst Consensus: Buy